Curium Receives Marketing Authorization In Switzerland For Piflufolastat (18F) – An Innovative PSMA PET Tracer Indicated In Patients With Prostate Cancer
Swissmedic grants marketing authorization for Piflufolastat (18F) in Switzerland e.imaging AG is marketing authorization holder and has exclusive distribution rights for Piflufolastat (18F) across Switzerland Curium announced today that it has marketing authorization in Switzerland for the distribution of Mehr